This 2024 cohort study assesses the diagnostic efficacy of a novel plasma phosphorylated tau 217 immunoassay in detecting Alzheimer disease pathology, demonstrating high accuracy in identifying tau pathology and potentially revolutionizing AD diagnosis through minimally invasive, blood-based testing.